Mobia Medical, Inc. Common Stock
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Mobia Medical, Inc. engages in the development and commercialization of implantable neurostimulation therapies for chronic ischemic stroke patients with upper limb motor deficits, focusing on the Vivistim Paired Vagus Nerve Stimulation (Paired VNS) System. The company markets an FDA-approved, implantable medical device that stimulates the vagus nerve during rehabilitation to enhance neuroplasticity and restore upper-extremity function, with the aim of establishing Vivistim as standard of care for eligible chronic stroke survivors. Mobia Medical operates primarily in the United States, with expansion activity and market development efforts directed at neurosurgical centers, rehabilitation facilities, and payer coverage to broaden adoption; its business model centers on device sales, professional services, and post-implant rehabilitation support. The company positions itself as a growth-stage medical device entity dedicated to improving outcomes for chronic stroke patients, supported by clinical data demonstrating meaningful functional gains and by ongoing clinician education, referral network development, and payer engagement initiatives. Mobia Medical was founded in 2007 and is headquartered in the United States, with subsidiary and affiliate activities aligned to regulatory and market access requirements across its core markets. The company’s product portfolio, market strategy, and growth trajectory reflect a focused emphasis on chronic stroke recovery through neuromodulation, with ongoing clinical and regulatory milestones to expand patient access and treatment adoption. The latest strategic updates include preparations for equity markets activity, continued expansion of direct implants, and advancement of surgeon and therapist training programs to support broader utilization of the Vivistim system.
Mobia Medical to Report Second Quarter 2026 Financial Results on August 11, 2026
Mobia Medical Appoints Reza Zadno, Ph.D., to its Board of Directors
Mobia Medical Announces Publication of Two-Year Data from VNS-REHAB Trial Demonstrating Durable and Continued Stroke Recovery with Vivistim® Paired VNS™ Therapy
Mobia Medical Announces Vivistim® Procedure Remains Assigned to New Technology APC 1580 under CMS Proposed 2027 Hospital Outpatient Prospective Payment System Rule
Primary Markets Group May 2026 U.S. IPO Monthly
Mobia Medical poised for commercial expansion, BofA says in initial coverage
Mobia Medical poised for commercial expansion, BofA says in initial coverage
Healthcare IPOs Raise $4.7 Billion As Odyssey, Mobia Debuts Slip
Mobia Medical: A Tough Debut For This Stroke Medical Business